How can Alzheimer's disease blood‐based biomarkers reach clinical practice?

Perneczky, Robert ; Quevenco, Frances‐Catherine ; Hendrix, James; Epelbaum, Stephane; Teunissen, Charlotte; Flier, Wiesje M. van der ; Suárez‐Calvet, Marc; Shi, Jiong; Mielke, Michelle M.; Iwatsubo, Takeshi; Palmqvist, Sebastian und Hansson, Oskar (2025): How can Alzheimer's disease blood‐based biomarkers reach clinical practice? In: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol. 17, No. 4, e70207

Abstract

INTRODUCTION

Alzheimer's disease (AD) diagnosis has been based largely on clinical symptoms, despite their limited sensitivity and specificity. Biomarker use was proposed to support a more accurate and timely diagnosis. However, neuroimaging or cerebrospinal fluid (CSF) is rarely used in primary care due to their perceived invasiveness, cost, and need for appropriate infrastructure. Blood-based biomarkers (BBMs) could represent an economical, minimally invasive alternative, but barriers exist to a seamless translation to the clinic.

METHODS

Ten international experienced AD clinicians and biomarker experts participated in a diagnostic roundtable to discuss the implementation of BBMs for diagnosing early symptomatic AD.

RESULTS

The participants proposed an optimal AD diagnostic pathway and highlighted three main gaps to implementing BBMs for early symptomatic AD diagnosis: limited real-world data, resource gaps, and system barriers.

DISCUSSION

Although BBMs could streamline the AD diagnostic pathway, further real-world evidence and collaboration among multiple stakeholders are needed.

• Item Type: Journal article
• Faculties: Medicine > Munich Cluster for Systems Neurology (SyNergy)
• Subjects: 600 Technology > 610 Medicine and health
• ISSN: 2352-8729
• Language: English
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198